Serous papillary peritoneal carcinoma: Unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review

Autor: Pentheroudakis, George, Pavlidis, Nicholas
Přispěvatelé: Pavlidis, Nicholas [0000-0002-2195-9961], Pentheroudakis, George [0000-0002-6632-2462]
Rok vydání: 2010
Předmět:
Oncology
Pathology
Protein bcl 2
Unclassified drug
Alkylating agent
Ca 125 antigen
Papillary
Cancer regression
Review
Cancer staging
Treatment response
Gene locus
Monoclonal antibody b.72.3
Ovarian neoplasms
Tumor suppresor wilms tumor 1
Gene overexpression
Peritoneal Neoplasm
Ovarian tumor
Neoplasms
Cell adhesion molecule
Cytoreductive surgery
Overall survival
Peritoneal Neoplasms
Protein p53
Ovarian Neoplasms
Unknown primary
Pancytokeratine
Neoplasms
Unknown Primary/diagnosis/metabolism/*pathology
Hematology
Tumor localization
Immunohistochemistry
Polymerase chain reaction
Serous fluid
Serous peritoneal papillary carcinoma
Female
Peritoneum
Peritoneal Neoplasms/diagnosis/metabolism/*pathology
Treatment indication
Carcinoma
Papillary/diagnosis/metabolism/*pathology
Human
Monoclonal antibody
Genomic instability
medicine.medical_specialty
Ovarian Neoplasms/diagnosis/metabolism/*pathology
Paclitaxel
Genotype
Ovary cancer
Serous papillary carcinoma
Oncoprotein
Unspecified side effect
Malignancy
Treatment duration
Cancer of unknown primary
Epidermal growth factor receptor 2
Protein ln21
Internal medicine
medicine
Carcinoma
Humans
Protein s 100
Gene mutation
Cyclophosphamide
Platinum
Gene deletion
business.industry
Cancer of unknown primary site
Brca1 protein
Epithelial membrane antigen
Cancer
Taxane derivative
medicine.disease
Gene frequency
Carcinoma
Papillary
Cancer survival
Cancer combination chemotherapy
Peritoneal neoplasms
Metabolism
Clinical feature
Heterozygosity loss
Doxorubicin
Membrane protein
Systematic review
Neoplasms
Unknown Primary
Ki 67 antigen
Cisplatin
business
Ovarian cancer
Gene function
Peritoneal carcinomatosis
Protein ln1
Zdroj: Critical reviews in oncology/hematology
ISSN: 1040-8428
DOI: 10.1016/j.critrevonc.2009.10.003
Popis: Introduction: Serous peritoneal papillary carcinoma (SPPC), though managed according to ovarian cancer therapeutic principles, has been variably considered as an ovarian cancer counterpart, a peritoneal malignancy with distinct characteristics or a cancer of unknown primary (CUP). Patients and methods: We systematically reviewed all publications studying molecular pathophysiology, clinical presentation, management and outcome of at least 10 patients with SPPC from 1980 to 2008 in anglophone medical journals and critically analysed the data. Results: Molecular profiling of CUP was performed in eight papers reporting on 211 patients with stage III/IV SPPC by means of immunohistochemistry or PCR-based assays. Twenty-five clinical series, mostly retrospetive, reported management and outcome of 579 patiens with SPPC, in several cases matched to advanced ovarian cancer controls. Though we did not identify statistically significant differences in molecular biology, clinical presentation, management and outcome of SPPC and ovarian cancer cases, some subtle differences emerged: patterns of loss of heterozygosity at several chromosomal loci differed from those seen in ovarian cancer, while the overexpression of the HER2 oncogene was encountered more often. Serous peritoneal tumours affected older patients and were more frequently multifocal or exhibited virulent clonal expansion in metastatic sites. Diffuse micronodular spread formed a high total load of malignancy in omental, peritoneal surfaces, difficult to debulk optimally. Despite effective chemotherapeutic cytoreduction and occasional long-term remissions, SPPC patients survived 2-6 months less than ovarian cancer patients. Conclusions: Patients with SPPC should not be classified in the poor-risk CUP category, in view of the therapeutic and prognostic differences. Still, the assimilation of the SPPC entity by ovarian cancer hindered further research into its genotypic and phenotypic characteristics that may differ from ovarian cancer. Subgroup analyses of large ovarian cancer trials may shed light in this issue. © 2009 Elsevier Ireland Ltd. 75 1 27 42
Databáze: OpenAIRE
Externí odkaz: